frontiers in Immunology

CORRECTION
published: 30 March 2021
doi: 10.3389/fimmu.2021.669616

Corrigendum: Activation of M1 Macrophages in Response to Recombinant TB Vaccines With Enhanced Antimycobacterial Activity

Shiu-Ju Yang[1], *Yih-Yuan Chen*[2], *Chih-Hao Hsu*[1], *Chia-Wei Hsu*[1], *Chun-Yu Chang*[1], *Jia-Ru Chang*[1] *and Horng-Yunn Dou*[1]*

[1] National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan, [2] Department of Biochemical Science and Technology, National Chiayi University, Chia-Yi, Taiwan

OPEN ACCESS

Edited and reviewed by:
Juraj Ivanyi,
King's College London.
United Kingdom

***Correspondence:**
Horng-Yunn Dou
hydou@nhri.edu.tw

Specialty section:
This article was submitted to Microbial Immunology, a section of the journal Frontiers in Immunology

Received: 19 February 2021
Accepted: 16 March 2021
Published: 30 March 2021

Citation:
Yang S-J, Chen Y-Y, Hsu C-H, Hsu C-W, Chang C-Y, Chang J-R and Dou H-Y (2021) Corrigendum: Activation of M1 Macrophages in Response to Recombinant TB Vaccines With Enhanced Antimycobacterial Activity. Front. Immunol. 12:669616. doi: 10.3389/fimmu.2021.669616

Keywords: recombinant Bacille Calmette–Guérin, *Mycobacterium tuberculosis*, innate immunity, macrophage, vaccine

A Corrigendum on

Activation of M1 Macrophages in Response to Recombinant TB Vaccines With Enhanced Antimycobacterial Activity

By Shiu-Ju Yang, Yih-Yuan Chen, Chih-Hao Hsu, Chia-Wei Hsu, Chun-Yu Chang, Jia-Ru Chang, Horng-Yunn Dou (2020) Front. Immunol. 23 June 2020 doi: 10.3389/fimmu.2020.01298

In the original article, there was a mistake in **Figure 4G**. When analyzing the original data, the authors mistakenly took raw data of the second image of 4G, which caused the third and second images to be duplicated. The corrected **Figure 4** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.



FIGURE 4 | Innate and adaptive immune cell profiles pulsed with tuberculosis-specific peptides from mice immunized with BCG, rBCG1, or rBCG2. C57BL/6 mice were immunized with BCG, rBCG1 or rBCG2 at weeks 0 and 2, and then challenged with H37Ra at week 4 (n = 6 to 7, in two independent experiments). At 2, 8, 12, and 20 weeks, the mice were sacrificed, and lungs were homogenized to single-cell suspensions. The cells were stimulated with tuberculosis-specific TB peptides (described in the Materials and Methods) for 68 h and then Golgi-stop for 4 h, stained for surface and intracellular markers, and then subjected to flow cytometry to determine the percentage of cytokine-producing cells within $CD4^+$ T cells. **(A)** Percentage of macrophages ($F4/80^+$ cells) in lung post-vaccination at week 8. **(B)** Percentage of macrophages ($F4/80^+$ cells) in lung post-vaccination at weeks 2 to 20. **(C)** Percentage of IFN-γ^+ cells in lung post-vaccination at week 12. **(D)** Percentage of IFN-γ^+ cells in lung post-vaccination at weeks 2 to 20. **(E)** Percentage of IL-4^+ cells in lung post-vaccination at week 12. **(F)** Percentage of IL-4^+ cells in lung post-vaccination at weeks 2 to 20. **(G)** Percentage of IL-17^+ T cells in lung post-vaccination at week 8. **(H)** Percentage of IL-17^+ T cells in lung post-vaccination at weeks 2 to 20. Differences among groups were determined by one-way or two-way ANOVA with a Tukey or Bonferroni *post hoc* test (***$P < .001$).